XREVIV represents a new frontier in personalized health optimization, integrating genetic science, blood biomarker analysis, ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...

Ultragenyx Pharmaceutical (RARE) remains unprofitable, with net losses expanding at an average annual rate of 14.8% over the past five years. Even as the company’s profit margin has yet to turn ...